TECOVIRIMAT (TPOXX) TREATMENT FOR MONKEYPOX
9.2022

Monkeypox Public Health Emergency

- In August 2022, U.S. officials declared Monkeypox a public health emergency.
- Currently no FDA-approved antiviral options exist to treat Monkeypox infections.
- Tecovirimat, an oral antiviral, is available under an expanded access IND protocol through the Strategic National Stockpile.
- HonorHealth has partnered with the Maricopa County Department of Public Health to stage tecovirimat treatment to meet the needs of members of our community.

Clinical Eligibility Requirements for Treatment

- Clinical eligibility criteria include:
  - Patients who have a documented positive monkeypox test
  - Patients who have clinical features associated with severe disease
    - High lesion burden, hemorrhagic disease, or confluent lesions
    - Disease involvement of anatomic areas that could result in serious sequelae, such as strictures or scarring
  - Patients who are at high risk for severe disease
    - HIV/AIDS, leukemia, malignancy, autoimmune disease, or on immunosuppressive therapy

How to Refer Your Patient for Tecovirimat Therapy

- As of **October 10th, 2022,** community physicians, emergency department physicians, and urgent care providers will be able to refer patients to HonorHealth Heuser Family Medicine Clinic to receive tecovirimat therapy.
- Use Epic referral RF253 or search for referrals using the synonyms "tecovirimat" "TPOXX" or "monkeypox".
- Upon receipt of referral, patients will be screened for clinical eligibility and the Heuser Clinic will reach out to patients to schedule appointments.
  - Appointments available Monday through Friday from 2pm to 4pm.